ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
Irvine, California – September 17, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint’s Read More
Agendia to Showcase New Data at the European Society for Medical Oncology Virtual Congress 2020
IRVINE, Calif., Sept. 14, 2020 /CNW/ - Agendia, Inc. a world leader in precision oncology for breast cancer today announced that new clinical data from its ongoing research in breast cancer is to be presented at the upcoming European Read More
MINDACT Study Shows MammaPrint® Provides Widespread Health System Cost Savings
Analysis Published in European Journal of Cancer Use of MammaPrint genomic assay alongside clinical assessment is cost-effective versus clinical assessment alone IRVINE, Calif., Aug. 25, 2020 - Agendia, Inc., a world leader in precision oncology for breast Read More
Agendia Included on the 2020 Inc. 5000 List With Three-Year Revenue Growth Approaching 90%
Inc. Magazine Unveils Its Annual List of America’s Fastest-Growing Private Companies—the Inc. 5000 NEW YORK, August 14, 2020 – This week, Inc. magazine revealed that Agendia, Inc. has been included on its annual Inc. 5000 Read More